Results 181 to 190 of about 39,319 (333)

Genetic Subtype‐Based International Prognostic Index Prognostic Model in Diffuse Large B‐Cell Lymphoma

MedComm, Volume 6, Issue 7, July 2025.
1. Genetic subtypes based on molecular subtyping correlated with prognosis in DLBCL. 2. Integrated genetic subtype‐based IPI model revealed prognostic discrimination. 3. New four‐category risk model defined for integrated model showed diverse prognosis.
Lan Mi, Jili Deng, Jiayue Qin, Chen Zhang, Lixia Liu, Shunli Yang, Libin Chen, Hua‐Jun Wu, Haojie Wang, Jun Zhu, Hong Chen, Feng Lou, Shanbo Cao, Yuqin Song, Weiping Liu   +14 more
wiley   +1 more source

Ibrutinib and Rituximab in Waldenström’s Macroglobulinemia [PDF]

New England Journal of Medicine, 2018
Gian Matteo Rigolin, Francesco Cavazzini, Antonio Cuneo   +2 more
openaire   +4 more sources

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source

Advancing Design Strategy of PROTACs for Cancer Therapy

MedComm, Volume 6, Issue 7, July 2025.
A comprehensive update on the PROTAC design, and highlighting the role of artificial intelligence in the PROTAC design for cancer therapy. ABSTRACT Proteolysis targeting chimeras (PROTACs) have emerged as a groundbreaking class of anticancer therapeutics.
Hang Luo, Yuan Tian, Razack Abdullah, Baoting Zhang, Yuan Ma, Ge Zhang   +5 more
wiley   +1 more source

Rilzabrutinib for the Treatment of Immune Thrombocytopenia

European Journal of Haematology, Volume 115, Issue 1, Page 4-15, July 2025.
ABSTRACT Advancements in the understanding of ITP pathogenesis have led to significant improvements in disease management through the use of both traditional immunosuppressive strategies and novel targeted therapies. However, a subset of patients remains refractory to treatment or achieves only transient benefits, underscoring the need for alternative ...
Caterina Labanca, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Francesco Mendicino, Giulio Caridà, Eugenio Lucia, Virginia Olivito, Veronica Manicardi, Nicola Amodio, Antonino Neri, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

, 2013
Betty Chang, Michelle Francesco, Martin F. M. de Rooij, Padmaja Magadala, Susanne Steggerda, Min Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham H. Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias   +14 more
openalex   +1 more source

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia [PDF]

, 2015
Sudhir Manda, Nancy M. Dunbar, Cynthia R. Marx‐Wood, Alexey V. Danilov   +3 more
openalex   +1 more source

Synthesis and Evaluation of Pseudoglucosinolates Releasing Isothiocyanates in the Presence of Azoreductases

ChemBioChem, Volume 26, Issue 12, June 16, 2025.
An expansion of the concept of pseudoglucosinolates (psGSLs) is reported introducing the first azoreductase‐responsive psGSL‐based probe releasing an isothiocyanate under simultaneous fluorescence turn‐on in the presence of AzoR, an azoreductase from Escherichia coli.
Aishi Chakrabarti, Charity S. G. Ganskow, Mervic D. Kagho, Claire. C. Jimidar, Lorenz Wiese, Neslihan Beyazit, Ulrike Beutling, Margarita Seeger, Silvana Smits, Stella Nyström, Anne Farewell, Anett Schallmey, Mark Brönstrup, Philipp Klahn   +13 more
wiley   +1 more source

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

, 2014
Lesley A. Mathews Griner, Rajarshi Guha, Paul Shinn, Ryan M. Young, Jonathan M. Keller, Dongbo Liu, Ian S. Goldlust, Adam Yasgar, Crystal McKnight, Matthew B. Boxer, Damien Y. Duveau, Jian‐kang Jiang, Sam Michael, Tim Mierzwa, Wenwei Huang, Martin J. Walsh, Bryan T. Mott, Paresma Patel, William Leister, David J. Maloney, Christopher A. LeClair, Ganesha Rai, Ajit Jadhav, Brian D. Peyser, Christopher P. Austin, Scott E. Martin, Anton Simeonov, Marc Ferrer, Louis M. Staudt, Craig J. Thomas   +29 more
openalex   +1 more source

Life after ibrutinib? A new unmet need in CLL [PDF]

, 2015
Javier Pinilla‐Ibarz, Julio C. Chávez
openalex   +1 more source